Studieoverzicht
Study name: INCLUSION ON HOLD: AMG757 (Amg20200469, DeLLphi-303) Tarlatamab
| Histology | SCLC |
|---|---|
| Tumor stage | Stage IV |
| Host / recruiting sites | UMC Groningen |
| Enrollment | Recruiting |
| Therapy line | First line (1L) |
| Design |
Open Label fase II |
| Intervention | Tarlatamab naast platinum etoposide en immuuntherapie |
| Key inclusion criteria | 1e lijn SCLC histologisch bewezen |
| Key exclusion criteria | symptomatische hersenmetastasen of slechte performance score |
| Contact information | Log in voor de contactinformatie |